Slowing nephropathy progression: Focus on proteinuria reduction

被引：92

作者：

Bakris, George L. ^{[1
]}

机构：

[1] Univ Chicago, Pritzker Sch Med, Hypertens Dis Unit, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA

来源：

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2008年 / 3卷

关键词：

D O I：

10.2215/CJN.03250807

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Blood pressure control reduces decline of kidney function. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers offer renoprotection to a small extent beyond that attributable to blood pressure lowering. These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their anti-proteinuric effect correlates with their additional renal benefits.

引用

收藏

页码：S3 / S10

页数：8

相关论文

共 34 条

[1]

[Anonymous], 2006, USRDS 2006 ANN DAT R

[2]

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy [J].

Atkins, RC ;

Briganti, EM ;

Lewis, JB ;

Hunsicker, LG ;

Braden, G ;

de Crespigny, PJC ;

DeFerrari, G ;

Drury, P ;

Locatelli, F ;

Wiegmann, TB ;

Lewis, EJ .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (02) :281-287

[3]

Bakris George L, 2002, J Clin Hypertens (Greenwich), V4, P420

[4]

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].

Barnett, AH ;

Bain, SC ;

Bouter, P ;

Karlberg, B ;

Madsbad, S ;

Jervell, J ;

Mustonen, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961

[5]

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[6]

Effect of inhibitors of the renin-angiotensin system and other anti hypertensive drugs on renal outcomes: systematic review and meta-analysis [J].

Casas, JP ;

Chua, WL ;

Loukogeorgakis, S ;

Vallance, P ;

Smeeth, L ;

Hingorani, AD ;

MacAllister, RJ .

LANCET, 2005, 366 (9502) :2026-2033

[7]

Is proteinuria a plausible target of therapy? [J].

Chua, DCY ;

Bakris, GL .

CURRENT HYPERTENSION REPORTS, 2004, 6 (03) :177-181

[8]

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy [J].

de Zeeuw, D ;

Remuzzi, G ;

Parving, HH ;

Keane, WF ;

Zhang, ZX ;

Shahinfar, S ;

Snapinn, S ;

Cooper, ME ;

Mitch, WE ;

Brenner, BM .

CIRCULATION, 2004, 110 (08) :921-927

[9]

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL [J].

de Zeeuw, D ;

Remuzzi, G ;

Parving, HH ;

Keane, WF ;

Zhang, ZX ;

Shahinfar, S ;

Snapinn, S ;

Cooper, MF ;

Mitch, WE ;

Brenner, BM .

KIDNEY INTERNATIONAL, 2004, 65 (06) :2309-2320

[10]

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial [J].

Eijkelkamp, Wouter B. A. ;

Zhang, Zhongxin ;

Remuzzi, Giuseppe ;

Parving, Hans-Henrik ;

Cooper, Mark E. ;

Keane, William F. ;

Shahinfar, Shahnaz ;

Gleim, Gilbert W. ;

Weir, Matthew R. ;

Brenner, Barry M. ;

de Zeeuw, Dick .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05) :1540-1546

← 1 2 3 4 →